Moderna’s Covid, RSV Vaccines Targeted in Two GSK Patent Suits

Moderna Inc.’s shots for Covid-19 and respiratory syncytial virus infringe as many as seven GSK Plc patents related to mRNA vaccine-delivery technology, the company said in a pair of federal lawsuits.

Two GSK units—GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC—allege multiple versions of SpikeVax infringe US Patent Nos. 11,324,770, 11,666,534, 11,786,467, and four others, according to a complaint filed Oct. 12 and docketed Tuesday in the US District Court for the District of Delaware.

They allege in a separate complaint that mResvia—Moderna’s vaccine for RSV, which infects the lungs and breathing passages—infringes six patents, including the ‘467 ...